Chris Huo Vaccination (2025)

1. Chris Huo posted on LinkedIn

  • Chris Huo's Post · BioNTech and Fosun Pharma to Potentially Supply 10 Million Doses of BioNTech's BNT162 mRNA-based Vaccine Candidate Against SARS-CoV-2 to Hong ...

  • Chris Huo posted on LinkedIn

Chris Huo posted on LinkedIn

2. COVID-19 vaccines are effective at preventing symptomatic and severe ...

  • 5 aug 2024 · Reported vaccine effectiveness against infection, symptomatic infection, and infection requiring hospitalisation were between 5 and 100 %, 34 ...

  • Health care workers (HCWs) have been at increased risk of infection during the SARS-CoV-2 pandemic and as essential workers have been prioritised for vaccination. Due to increased exposure HCW are considered a predictor of what might happen in the ...

COVID-19 vaccines are effective at preventing symptomatic and severe ...

3. Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits ...

  • A vaccine developed by removing glycan shields in the SARS-CoV-2 S protein conferred protection against infection with variants of concern. A sugar-free vaccine.

  • A major challenge to end the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is to develop a broadly protective vaccine that elicits long-term immunity. As the key immunogen, the viral surface spike (S) protein is ...

Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits ...

4. Omicron infection following vaccination enhances a broad ...

  • 21 aug 2023 · Recent reports have suggested that omicron-specific immunity generated by breakthrough infections may be muted in triple-vaccinated individuals, ...

  • Pronounced immune escape by the SARS-CoV-2 Omicron variant has resulted in many individuals possessing hybrid immunity, generated through a combination of vaccination and infection. Concerns have been raised that omicron breakthrough infections in triple-vaccinated individuals result in poor induction of omicron-specific immunity, and that prior SARS-CoV-2 infection is associated with immune dampening. Taking a broad and comprehensive approach, we characterize mucosal and blood immunity to spike and non-spike antigens following BA.1/BA.2 infections in triple mRNA-vaccinated individuals, with and without prior SARS-CoV-2 infection. We find that most individuals increase BA.1/BA.2/BA.5-specific neutralizing antibodies following infection, but confirm that the magnitude of increase and post-omicron titres are higher in the infection-naive. In contrast, significant increases in nasal responses, including neutralizing activity against BA.5 spike, are seen regardless of infection history. Spike-specific T cells increase only in infection-naive vaccinees; however, post-omicron T cell responses are significantly higher in the previously-infected, who display a maximally induced response with a highly cytotoxic CD8+ phenotype following their 3rd mRNA vaccine dose. Responses to non-spike antigens increase significantly regardless of prior infection status. These findings suggest that hybrid immunity induced by omicron breakthrough infections is characterized by significant immune enhan...

Omicron infection following vaccination enhances a broad ...

5. Vaccination against Shigella and ETEC: novel antigens ... - CORDIS

Vaccination against Shigella and ETEC: novel antigens ... - CORDIS

6. Optimal timing of influenza vaccination in young children - The BMJ

  • 21 feb 2024 · Children born in October were most likely to be vaccinated in October and least likely to have a diagnosis of influenza, consistent with recommendations ...

  • Objective To assess optimal timing of influenza vaccination in young children. Design Population based cohort study. Setting United States. Participants Commercially insured children aged 2-5 years who were vaccinated against influenza during 2011-18. Main outcome measure Rates of diagnosis of influenza among children who were vaccinated against influenza, by birth month. Results Overall, 819 223 children aged 2-5 received influenza vaccination. Children vaccinated in November and December were least likely to have a diagnosis of influenza, a finding that may be confounded by unmeasured factors that influence the timing of vaccination and risk of influenza. Vaccination commonly occurred on days of preventive care visits and during birth months. Children born in October were disproportionately vaccinated in October and were, on average, vaccinated later than children born in August and earlier than those born in December. Children born in October had the lowest rate of influenza diagnosis (for example, 2.7% (6016/224 540) versus 3.0% (6462/212 622) for those born in August; adjusted odds ratio 0.88, 95% confidence interval 0.85 to 0.92). Conclusions In a quasi-experimental analysis of young children vaccinated against influenza, birth month was associated with the timing of vaccination through its influence on the timing of preventive care visits. Children born in October were most likely to be vaccinated in October and least likely to have a diagnosis of influenza, cons...

Optimal timing of influenza vaccination in young children - The BMJ

7. Examining the Immunological Effects of COVID-19 Vaccination in ...

  • 23 aug 2021 · ... Huo Family Foundation and The National Institute for Health Research (UKRIDHSC COVID-19 Rapid Response Rolling Call, Grant Reference Number ...

  • SARS-COV-2 vaccines have been shown to be efficacious primarily in healthy volunteer populations and population level studies. Immune responses following SARS-C

Examining the Immunological Effects of COVID-19 Vaccination in ...

8. Christopher Wheldon | Fox Chase Cancer Center - Philadelphia PA

  • ... vaccination, cancer screening) and healthcare delivery (e.g., cancer ... Huo, J., & Bian, J. (2019). How to Improve Public Health via Mining Social ...

  • Assistant Professor, Social and Behavioral Sciences

9. Christopher Wheldon | Temple University

  • ... vaccination, cancer screening) and healthcare delivery (e.g., cancer ... Huo, J., & Bian, J. (2019). How to Improve Public Health via Mining Social ...

  • Temple University

10. [PDF] T cell and antibody responses induced by a single dose of ...

  • philanthropic donations to the University of Oxford, including the Huo ... (DHSC) Joint Committee on Vaccination & Immunisation (JCVI), but does not participate ...

11. A COVID-19 vaccine candidate using SpyCatcher multimerization of the ...

  • ... Chris Chiu, Ryan Waters, Ashley Gray, Mehreen Azhar, Valerie Mioulet, Joseph ... Graham, Helen M.E. Duyvesteyn, Tomas Malinauskas, Jiandong Huo, Julia A.

  • Tiong Kit Tan*, Pramila Rijal, Rolle Rahikainen, Anthony H. Keeble, Lisa Schimanski, Saira Hussain, Ruth Harvey, Jack W.P. Hayes, Jane C. Edwards, Rebecca K. McLean, Veronica Martini, Miriam Pedrera, Nazia Thakur, Carina Conceicao, Isabelle Dietrich, Holly Shelton, Anna Ludi, Ginette Wilsden, Clare Browning, Adrian K. ZagrajekDagmara Bialy, Sushant Bhat, Phoebe Stevenson-Leggett, Philippa Hollinghurst, Matthew Tully, Katy Moffat, Chris Chiu, Ryan Waters, Ashley Gray, Mehreen Azhar, Valerie Mioulet, Joseph Newman, Amin S. Asfor, Alison Burman, Sylvia Crossley, John A. Hammond, Elma Tchilian, Bryan Charleston, Dalan Bailey, Tobias J. Tuthill, Simon P. Graham, Helen M.E. Duyvesteyn, Tomas Malinauskas, Jiandong Huo, Julia A. Tree, Karen R. Buttigieg, Raymond J. Owens, Miles Carroll, Rodney S. Daniels, John W. McCauley, David I. Stuart, Kuan Ying A. Huang, Mark Howarth, Alain R. Townsend

A COVID-19 vaccine candidate using SpyCatcher multimerization of the ...

12. Evaluation of the immunogenicity of prime-boost vaccination with the ...

  • ... Chris Chiu, Joseph Newman, Amin S. Asfor, Alison Burman, Sylvia Crossley, Jiandong Huo, Raymond J. Owens, Miles Carroll, John A. Hammond, Elma Tchilian ...

  • Simon P. Graham*, Rebecca K. McLean, Alexandra J. Spencer, Sandra Belij-Rammerstorfer, Daniel Wright, Marta Ulaszewska, Jane C. Edwards, Jack W.P. Hayes, Veronica Martini, Nazia Thakur, Carina Conceicao, Isabelle Dietrich, Holly Shelton, Ryan Waters, Anna Ludi, Ginette Wilsden, Clare Browning, Dagmara Bialy, Sushant Bhat, Phoebe Stevenson-LeggettPhilippa Hollinghurst, Ciaran Gilbride, David Pulido, Katy Moffat, Hannah Sharpe, Elizabeth Allen, Valerie Mioulet, Chris Chiu, Joseph Newman, Amin S. Asfor, Alison Burman, Sylvia Crossley, Jiandong Huo, Raymond J. Owens, Miles Carroll, John A. Hammond, Elma Tchilian, Dalan Bailey, Bryan Charleston, Sarah C. Gilbert, Tobias J. Tuthill, Teresa Lambe

Evaluation of the immunogenicity of prime-boost vaccination with the ...

13. How COVID-19 vaccine supply chains emerged in the midst of a pandemic

  • Levin & Christopher M. Snyder, 2020. "Designing Advance Market Commitments ... Bonadio, Barthélémy & Huo, Zhen & Levchenko, Andrei A. & Pandalai-Nayar ...

  • Many months after COVID-19 vaccines were first authorized for public use, still limited supplies could only partially reduce the devastating loss of life and economic costs caused by the pandemic. Cou

How COVID-19 vaccine supply chains emerged in the midst of a pandemic

14. Evaluation of the immunogenicity of prime-boost vaccination ... - bioRxiv

  • 20 jun 2020 · ... vaccination with the replication ... Chris Chiu, Joseph Newman, Amin S. Asfor, Alison Burman, Sylvia Crossley, Jiandong Huo, Raymond J.

  • Clinical development of the COVID-19 vaccine candidate ChAdOx1 nCoV-19, a replication-deficient simian adenoviral vector expressing the full-length SARS-CoV-2 spike (S) protein was initiated in April 2020 following non-human primate studies using a single immunisation. Here, we compared the immunogenicity of one or two doses of ChAdOx1 nCoV-19 in both mice and pigs. Whilst a single dose induced antigen-specific antibody and T cells responses, a booster immunisation enhanced antibody responses, particularly in pigs, with a significant increase in SARS-CoV-2 neutralising titres. ### Competing Interest Statement Sarah Gilbert and Teresa Lambe are named on a patent application covering ChAdOx1 nCoV-19. The remaining authors declare no competing interests. The funders played no role in the conceptualisation, design, data collection, analysis, the decision to publish, or preparation of the manuscript.

Evaluation of the immunogenicity of prime-boost vaccination ... - bioRxiv

15. Week in Politics: An anxious wait for vaccines | RNZ News

  • 28 mei 2021 · ... Covid-19 vaccine will arrive to keep the rollout going. Chris Hipkins gets his first jab of the Pfizer-BioNTech Covid-19 vaccine. Chris ...

  • Analysis - The political stakes are sky high as the government waits anxiously for confirmation from Pfizer that enough of the Covid-19 vaccine will arrive to keep the rollout going.

Week in Politics: An anxious wait for vaccines | RNZ News

16. Yanan Huo on LinkedIn: Hypothesis testing and sample size ...

  • 20 jul 2024 · ... vaccination and drugs they produce and health workers have good ... Christopher Ring. Visiting Lecturer in Infectious Diseases. 1mo.

  • 🎉 Exciting News! 🎉 I am thrilled to announce the publication of our latest paper in BMC Medical Research Methodology: "Hypothesis Testing and Sample Size…

Yanan Huo on LinkedIn: Hypothesis testing and sample size ...

17. Persistence of S1 Spike Protein in CD16+ Monocytes up to 245 Days ...

  • 24 mrt 2024 · ... vaccination patients from all 4 vaccine manufacturers contained S1, S1 mutant and S2 peptide sequences. Post-COVID vaccination individuals ...

  • There have been concerning reports about people experiencing new onset persistent complications (greater than 30 days) following approved SARS-CoV-2 vaccines (BNT162b2 (Pfizer), mRNA-1273 (Moderna), Janssen (Johnson and Johnson), and ChAdOx1 nCoV-19 (AstraZeneca)). We sought to determine the immunologic abnormalities in these patients and to investigate whether the potential etiology was similar to Post-Acute Sequalae of COVID (PASC), or long COVID. We studied 50 individuals who received one of the approved COVID-19 vaccines and who experienced new onset PASC-like symptoms along with 45 individuals post-vaccination without symptoms as controls. We performed multiplex cytokine/chemokine profiling with machine learning as well as SARS-CoV-2 S1 protein detection on CD16+ monocyte subsets using flow cytometry and mass spectrometry. We determined that post-vaccination individuals with PASC- like symptoms had similar symptoms to PASC patients. When analyzing their immune profile, Post-vaccination individuals had statistically significant elevations of sCD40L (p<0.001), CCL5 (p=0.017), IL-6 (p=0.043), and IL-8 (p=0.022). Machine learning characterized these individuals as PASC using previously developed algorithms. Of the S1 positive post-vaccination patients, we demonstrated by liquid chromatography/ mass spectrometry that these CD16+ cells from post-vaccination patients from all 4 vaccine manufacturers contained S1, S1 mutant and S2 peptide sequences. Post-COVID vaccination indiv...

Persistence of S1 Spike Protein in CD16+ Monocytes up to 245 Days ...

18. Optimal Vaccine Subsidies for Endemic and Epidemic Diseases

  • Michael Kremer · Christopher Mark Snyder · Heidi L. Williams. Abstract. Vaccines exert a positive externality, reducing spread of disease from the consumer ...

  • Vaccines exert a positive externality, reducing spread of disease from the consumer to others, providing a rationale for subsidies. We study how optimal subsidies vary with disease characteristics by

Optimal Vaccine Subsidies for Endemic and Epidemic Diseases
Chris Huo Vaccination (2025)

References

Top Articles
Latest Posts
Recommended Articles
Article information

Author: Arielle Torp

Last Updated:

Views: 5547

Rating: 4 / 5 (41 voted)

Reviews: 80% of readers found this page helpful

Author information

Name: Arielle Torp

Birthday: 1997-09-20

Address: 87313 Erdman Vista, North Dustinborough, WA 37563

Phone: +97216742823598

Job: Central Technology Officer

Hobby: Taekwondo, Macrame, Foreign language learning, Kite flying, Cooking, Skiing, Computer programming

Introduction: My name is Arielle Torp, I am a comfortable, kind, zealous, lovely, jolly, colorful, adventurous person who loves writing and wants to share my knowledge and understanding with you.